Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353912 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 571
- Enrollment target
NCT00353912: Completed Phase 3 study, sponsored by Novartis.
NCT00353912 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 571 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00353912, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 571 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Interventions
- DRUG valsartan + amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
What the finished NCT00353912 record still lists
NCT00353912 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 1 intervention - of which valsartan + amlodipine is the first listed.
NCT00353912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00353912 about?
NCT00353912 is a clinical study titled "Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension". The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
What is the current status of trial NCT00353912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 571 participants. The study started on 2006-06. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00353912?
The interventions under investigation include: valsartan + amlodipine (DRUG).
Who is sponsoring clinical trial NCT00353912?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00353912's enrollment target sits among peer trials
571 665th of 2000 higher than 1,336 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia